Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.33 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278594 | 0.99 | PDE6D (0.37) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL22969681 | 0.99 | PDE6D (0.37) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL17278549 | 0.99 | PDE6D (0.37) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL22308743 | 0.94 | MEN1 (0.45) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL25774961 | 0.94 | L3MBTL1 (0.45) | L3MBTL1MAPTPDE6DLMNAEGLN1 | |
| SCHEMBL22309919 | 0.94 | MEN1 (0.45) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL22308742 | 0.94 | MEN1 (0.45) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13833106 | 0.94 | MEN1 (0.36) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL13833099 | 0.94 | MEN1 (0.36) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL17278546 | 0.93 | L3MBTL1 (0.42) | L3MBTL1MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917910-B2 | Organic compound and organic electroluminescent device using the same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11917910-B2 | Organic compound and organic electroluminescent device using the same | SOLUS ADVANCED MATERIALS CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917910-B2 | Organic compound and organic electroluminescent device using the same | VDAC1, OR10J3, PIEZO1 | L3MBTL1 355/4885MAPT 660/4885MEN1 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.